We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel Multiplex Immunoassay Developed for Chagas Disease

By LabMedica International staff writers
Posted on 21 Apr 2016
Print article
Image: The SensoSpot microarray analyzer (Photo courtesy of Sensovation).
Image: The SensoSpot microarray analyzer (Photo courtesy of Sensovation).
Different tests are available for the diagnosis of Chagas disease in the clinic or for screening of blood donations. Direct detection of parasite Trypanosoma cruzi in the blood is performed by microscopy, hemoculture, xenodiagnoses, or detection of the parasite’s nucleic acids.

These assays are highly specific but lack sensitivity in the chronic stage during which parasites load in the blood is reduced and therefore, diagnosis of T. cruzi infection is usually made indirectly by the detection of specific antibodies to T. cruzi antigens using enzyme-linked immunosorbent assays.

Scientists from InfYnity Biomarkers (Lyon, France) working with their Brazilian colleagues tested 248 positive samples T. cruzi, 94 unscreened blood donors’ samples from non-endemic area, 49 seronegative blood donors, 7 false-positive and 3 doubtful samples. They designed a novel array of twelve antigens and printed these antigens onto 96-well plates using a sciFLEXARRAYER printing system (SCIENION; Berlin, Germany). Multi- cruzi Chagas ELISA assays were performed and each plate was imaged then analyzed using the SensoSpot Microarray Analyzers (Sensovation; Radolfzell, Germany).

Among the 200 cardiomyopathy samples, only 194 could be characterized as either negative (67%) or positive (33%) by polymerase chain reaction (PCR). Additionally, among the 48 screening-positive blood donors, 34 were PCR negative (71%) and 14 were PCR positive (29%). PCR techniques were different for both populations. The observed reactivities were analyzed to propose a decision-tree algorithm that correctly classifies all the samples, with the potential to discriminate false-positive results and sticky samples. The team observed that antibodies levels (Sum of all antigens) were significantly higher for PCR positive than for PCR negative samples in all studied groups with Multi-cruzi Chagas ELISA.

The authors concluded that the results described in their study indicate that the Multi-cruzi improves the serological confirmation of Chagas disease. Moreover, the “sum of all antigens” detected by Multi-cruzi could reflect parasitemia level in patients, similar to PCR signals, and could serve as an indicator of parasite clearance in longitudinal follow- ups. Validation of this assay is still required on an independent large collection of well-characterized samples including typical false-reactive samples such as Leishmaniasis. The study was published on April 1, 2016, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
InfYnity Biomarkers
SCIENION
Sensovation

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The new method could reduce undiagnosed cancer cases in less-developed regions (Photo courtesy of 123RF)

New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis

Globally, more than one billion people suffer from a high rate of missed disease diagnosis, highlighting the urgent need for more precise and affordable diagnostic tools. Such tools are especially crucial... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.